144 related articles for article (PubMed ID: 11786656)
21. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
22. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
[TBL] [Abstract][Full Text] [Related]
23. Nosocomial infection caused by vancomycin-susceptible multidrug-resistant Enterococcus faecalis over a long period in a university hospital in Japan.
Kudo M; Nomura T; Yomoda S; Tanimoto K; Tomita H
Microbiol Immunol; 2014 Nov; 58(11):607-14. PubMed ID: 25145983
[TBL] [Abstract][Full Text] [Related]
24. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
Arias CA; Singh KV; Panesso D; Murray BE
Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
[TBL] [Abstract][Full Text] [Related]
25. [Antibiotic Resistance of Enterococci Isolated from Healthy Humans and Patients with Various Pathologies.].
Sycheva MV; Kartashova OL; Shchepitova NE; Safronov AA
Antibiot Khimioter; 2016; 61(7-8):27-32. PubMed ID: 29533558
[TBL] [Abstract][Full Text] [Related]
26. Insight into antimicrobial susceptibility and population structure of contemporary human Enterococcus faecalis isolates from Europe.
Kuch A; Willems RJ; Werner G; Coque TM; Hammerum AM; Sundsfjord A; Klare I; Ruiz-Garbajosa P; Simonsen GS; van Luit-Asbroek M; Hryniewicz W; Sadowy E
J Antimicrob Chemother; 2012 Mar; 67(3):551-8. PubMed ID: 22207599
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
Verbist L; Verhaegen J
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
[TBL] [Abstract][Full Text] [Related]
28. Aminoglycoside resistant enterococcal endocarditis.
Eliopoulos GM
Infect Dis Clin North Am; 1993 Mar; 7(1):117-33. PubMed ID: 8463648
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial resistance profiles of Enterococcus faecalis and Enterococcus faecium isolated from artisanal food of animal origin in Argentina.
Delpech G; Pourcel G; Schell C; De Luca M; Basualdo J; Bernstein J; Grenovero S; Sparo M
Foodborne Pathog Dis; 2012 Oct; 9(10):939-44. PubMed ID: 22953740
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial resistance of Enterococci in Lebanon.
Zouain MG; Araj GF
Int J Antimicrob Agents; 2001 Mar; 17(3):209-13. PubMed ID: 11282266
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing determination of high-level aminoglycoside resistance in Enterococcus faecalis.
Sahm DF; Boonlayangoor S; Iwen PC; Baade JL; Woods GL
J Clin Microbiol; 1991 Sep; 29(9):1934-9. PubMed ID: 1774318
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility profile of Enterococcus faecalis isolated at the Lagos University Teaching Hospital, Nigeria.
Iregbu KC; Ogunsola FT; Odugbemi TO
Niger Postgrad Med J; 2002 Sep; 9(3):125-8. PubMed ID: 12501265
[TBL] [Abstract][Full Text] [Related]
34. Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities.
Babalola CP; Patel KB; Nightingale CH; Nicolau DP
Int J Antimicrob Agents; 2004 Apr; 23(4):343-8. PubMed ID: 15081082
[TBL] [Abstract][Full Text] [Related]
35. Consequences of VanE-type resistance on efficacy of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecalis.
Lafaurie M; Perichon B; Lefort A; Carbon C; Courvalin P; Fantin B
Antimicrob Agents Chemother; 2001 Oct; 45(10):2826-30. PubMed ID: 11557476
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci.
Noviello S; Ianniello F; Esposito S
J Antimicrob Chemother; 2001 Aug; 48(2):283-6. PubMed ID: 11481302
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
38. Antibiotic susceptibility of periodontal Enterococcus faecalis.
Rams TE; Feik D; Mortensen JE; Degener JE; van Winkelhoff AJ
J Periodontol; 2013 Jul; 84(7):1026-33. PubMed ID: 23106507
[TBL] [Abstract][Full Text] [Related]
39. Resistance to aminoglycosides and other antibiotics among clinical isolates of Enterococcus spp.
Tripodi MF; Rambaldi A; Utili R; Rosario P; Attanasio V; Locatelli A; Adinolfi LE; Andreana A; Florio A; Ruggiero G
New Microbiol; 1995 Jul; 18(3):319-23. PubMed ID: 7553370
[TBL] [Abstract][Full Text] [Related]
40. [Susceptibility of Enterococcus genus to new antimicrobial agents].
Sánchez-Molina MI; Martín D; Valladares C; Gastañares MJ; Torres C; Borque L
Rev Esp Quimioter; 2004 Jun; 17(2):184-8. PubMed ID: 15470513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
